Allozymes secures $15M Series A funding to expand its Enzyme Screening Technology
Allozymes, a pioneering biotech startup, has just closed a remarkable $15 million Series A funding round, propelling its transformative enzyme screening technology into the spotlight. This investment marks a significant milestone for the company, positioning it to evolve from a valuable service provider to a global leader in bio-based chemical innovation.
Allozymes, a pioneering biotech startup, has just closed a remarkable $15 million Series A funding round, propelling its transformative enzyme screening technology into the spotlight. This investment marks a significant milestone for the company, positioning it to evolve from a valuable service provider to a global leader in bio-based chemical innovation.
